CORONA Remedies moves up on starting additional commercial production of tablets at Bhayla facility
CORONA Remedies is currently trading at Rs. 1365.80, up by 9.15 points or 0.67% from its previous closing of Rs. 1356.65 on the BSE.
The scrip opened at Rs. 1360.00 and has touched a high and low of Rs. 1370.15 and Rs. 1360.00 respectively. So far 1180 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1499.00 on 15-Dec-2025 and a 52 week low of Rs. 1340.20 on 18-Dec-2025.
Last one week high and low of the scrip stood at Rs. 1480.50 and Rs. 1340.20 respectively. The current market cap of the company is Rs. 8297.28 crore.
The promoters holding in the company stood at 69.00%, while Institutions and Non-Institutions held 4.64% and 26.37% respectively.
CORONA Remedies has successfully commenced the additional commercial production of tablets/capsules at the Bhayla manufacturing facility (Facility) of the company. As on March 31, 2025, the Facility has an installed capacity of 852.80 million with the available capacity of 600 million and actual production of 561.49 million which is equivalent to capacity utilization of 93.58%. The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the Facility.
The additional commercial production will add a significant milestone in the company’s strategic expansion to augment the upcoming market demands, enhance the in-house production capabilities and improve the supply chain agility. The commercialized additional capacity is entirely being funded through internal accruals.
Corona Remedies is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas.
.jpg)
